Kelly Morgan, MS, CGC, on Improving Family Discussions on Genetic Risk for Cancer

Video

The MSK expert explained that pre- and post-test education on genetic testing also improved family discussions about their risk.


Pre- and post-test education on genetic testing may help spark conversations among those who may be at risk for cancer, according to Kelly Morgan, MS, CGC.

In a recent study, presented at the 2020 ASCO Virtual Scientific Program, the BRCA Founder OutReach (BFOR) offered pre-testing online education with posttest engagement of primary care providers, which appeared to be effective in educating both patients and providers alike.

In a recent interview with CancerNetwork, Morgan, genetic counselor at Memorial Sloan Kettering Cancer Center, discussed how using telehealth for genetic testing education can assist in family discussions surrounding cancer risk.

Transcription:

You know, you could imagine, if you will, that a tool like this where people can access medical information that's very detailed from home is something that could lend itself well to being shared with family.

One of the things along those lines that we learned from this study that's very interesting is, I mentioned that about 3.4% of participants tested positive. When we look at that group, over half, so actually over 60%, had a family mutation. So that would suggest that many individuals are taking advantage of this model to go forward with testing for what was already in their family. So we might imagine that this testing might have been primarily up took by individuals who didn't have any known risks and we're hearing about for the first time, but rather, it seems to be a tool that actually lends itself pretty well to spreading genetic test and genetic information within a family.

Recent Videos
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
Byoung Chul Cho, MD, PhD, highlights ongoing trials assessing intravenous and subcutaneous amivantamab in EGFR-mutant non–small cell lung cancer.
An AI-based system may reduce the time needed to match patients with cancer to suitable clinical trials.
Related Content